dimethyl sulfide has been researched along with Cystinosis in 4 studies
dimethyl sulfide: structure
dimethyl sulfide : A methyl sulfide in which the sulfur atom is substituted by two methyl groups. It is produced naturally by some marine algae.
methyl sulfide : Any aliphatic sulfide in which at least one of the organyl groups attached to the sulfur is a methyl group.
Cystinosis: A metabolic disease characterized by the defective transport of CYSTINE across the lysosomal membrane due to mutation of a membrane protein cystinosin. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. In the KIDNEY, nephropathic cystinosis is a common cause of RENAL FANCONI SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Halitosis due to dimethylsulfide (DMS) generation is a major side effect of cysteamine in the treatment of cystinosis." | 7.78 | Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate. ( Besouw, M; Cornelissen, E; Levtchenko, E; Rioux, P; Tangerman, A, 2012) |
| "To identify breath sulphur compounds causing halitosis induced by cysteamine therapy in patients with cystinosis." | 7.74 | The origin of halitosis in cystinotic patients due to cysteamine treatment. ( Besouw, M; Blom, H; de Graaf-Hess, A; Levtchenko, E; Tangerman, A, 2007) |
| "Cystinosis is a genetic disorder caused by malfunction of cystinosin and is characterized by accumulation of cystine." | 5.46 | Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. ( Hartman, TM; Ivanova, EA; Levtchenko, EN; Pastore, A; Paul, P; Price, NPJ; Ramazani, Y; Van Den Heuvel, L; Van Schepdael, A, 2017) |
| "When cysteamine was given every 6 h, the leukocyte cystine concentration, measured 5-7 h after a dose, decreased with increasing cysteamine doses up to 17 mg/kg; at this dose the cystine value was 1." | 5.29 | Intravenous cysteamine therapy for nephropathic cystinosis. ( Bernardini, I; Gahl, WA; Hyman, PE; Ingelfinger, J; Mohan, P; Tangerman, A, 1995) |
| "Halitosis due to dimethylsulfide (DMS) generation is a major side effect of cysteamine in the treatment of cystinosis." | 3.78 | Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate. ( Besouw, M; Cornelissen, E; Levtchenko, E; Rioux, P; Tangerman, A, 2012) |
| "To identify breath sulphur compounds causing halitosis induced by cysteamine therapy in patients with cystinosis." | 3.74 | The origin of halitosis in cystinotic patients due to cysteamine treatment. ( Besouw, M; Blom, H; de Graaf-Hess, A; Levtchenko, E; Tangerman, A, 2007) |
| "Cystinosis is a genetic disorder caused by malfunction of cystinosin and is characterized by accumulation of cystine." | 1.46 | Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. ( Hartman, TM; Ivanova, EA; Levtchenko, EN; Pastore, A; Paul, P; Price, NPJ; Ramazani, Y; Van Den Heuvel, L; Van Schepdael, A, 2017) |
| "When cysteamine was given every 6 h, the leukocyte cystine concentration, measured 5-7 h after a dose, decreased with increasing cysteamine doses up to 17 mg/kg; at this dose the cystine value was 1." | 1.29 | Intravenous cysteamine therapy for nephropathic cystinosis. ( Bernardini, I; Gahl, WA; Hyman, PE; Ingelfinger, J; Mohan, P; Tangerman, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramazani, Y | 1 |
| Levtchenko, EN | 1 |
| Van Den Heuvel, L | 1 |
| Van Schepdael, A | 1 |
| Paul, P | 1 |
| Ivanova, EA | 1 |
| Pastore, A | 1 |
| Hartman, TM | 1 |
| Price, NPJ | 1 |
| Besouw, M | 2 |
| Tangerman, A | 3 |
| Cornelissen, E | 1 |
| Rioux, P | 1 |
| Levtchenko, E | 2 |
| Blom, H | 1 |
| de Graaf-Hess, A | 1 |
| Gahl, WA | 1 |
| Ingelfinger, J | 1 |
| Mohan, P | 1 |
| Bernardini, I | 1 |
| Hyman, PE | 1 |
4 other studies available for dimethyl sulfide and Cystinosis
| Article | Year |
|---|---|
Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis.
Topics: Arabinose; Biotransformation; Cysteamine; Cystine Depleting Agents; Cystinosis; Drug Design; Extrace | 2017 |
Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
Topics: Adolescent; Child; Cysteamine; Cystinosis; Exhalation; Halitosis; Humans; Male; Sulfides; Young Adul | 2012 |
The origin of halitosis in cystinotic patients due to cysteamine treatment.
Topics: Adolescent; Adult; Breath Tests; Child; Cysteamine; Cystinosis; Female; Halitosis; Humans; Male; Sul | 2007 |
Intravenous cysteamine therapy for nephropathic cystinosis.
Topics: Child, Preschool; Cysteamine; Cystine; Cystinosis; Gastrointestinal Diseases; Gastrointestinal Motil | 1995 |